Rezolute, Inc. heads into tonight's earnings release with short sellers adding pressure just as the company's lead drug candidate faces its most consequential test.
Short interest is the dominant signal here. It has climbed to 15.1% of the free float — up 11.6% on the week and 8% in a single session on May 11 — after spending most of April on a steady decline from a peak near 22% in early April. The borrow remains easy to access: cost to borrow is a modest 0.56% and availability is ample, meaning new short positions are cheap to establish. Days to cover of 9.4 points to how long an unwind would take if sentiment reversed sharply. The ORTEX short score has drifted higher all week, reaching 59.4 — not extreme, but a consistent direction of travel that aligns with the positioning build.
Options traders are not pressing the bearish case nearly as hard. The put/call ratio is running at 0.156, barely above its 20-day average of 0.138 and less than a standard deviation above it. Call volume continues to dominate the options market, with the PCR sitting near the bottom of its 52-week range. That skew describes a crowd holding for upside, even as the stock has pulled back 9% over the past month to close at $3.30 — recovering 4.1% on Tuesday alone ahead of the report.
The debate centres squarely on ersodetug. Bulls point to early-access programme data in tumour-induced hypoglycemia and a streamlined Phase 3 design as evidence the path to approval is becoming clearer. Wedbush upgraded the name to Outperform in late March with a $5.00 target, the most recent analyst action on record. Six of nine covering analysts carry Buy-equivalent ratings, with a consensus mean target near $5.10 — roughly 55% above the current price. Bears counter with the Phase 3 CHI trial failure, where a surprisingly high placebo effect undermined the efficacy read-across, and note that the company generates no revenue. Guggenheim and HC Wainwright both slashed targets sharply in December — from $15 and $14 to $6 and $5 respectively — though they maintained Buy ratings; those targets, now several months old, should be read with that context in mind.
Institutional ownership adds a layer of structural support. Federated Hermes holds nearly 16% of shares, RA Capital — a specialist healthcare fund — built a position of 8.8%, and Opaleye added aggressively, with last-reported net buys of over 5.3 million shares. Insider activity has been muted more recently: the CFO bought $28,500 worth of stock at $2.85 in late March, a small signal of confidence at a lower price. The stock has since rallied above that level.
Past earnings reactions have been asymmetric. February's update produced a single-day gain of nearly 14%, which then gave back to a five-day return of -2.7%. The November 2025 print fell 9% over five days. Tonight's release tests whether the programme data is clean enough to sustain the call-heavy, low-put positioning that options traders have built — or whether the bear thesis on clinical risk reasserts itself.
See the live data behind this article on ORTEX.
Open RZLT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
